Investigational drug · Phase 3
Opevesostat
Also called: MK-5684, ODM-208
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
12
Any phase or sponsor naming "Opevesostat"
First trial start
2018
Mar 19, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Opevesostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer Metastatic
- Malignant Neoplasm
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Castration-Resistant Prostatic Cancer
- Metastasis
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Opevesostat" as an intervention, largest first.
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136650 · 1,314 participants (planned) · Start Dec 18, 2023 · Primary completion May 10, 2028
Drug: Opevesostat; Dexamethasone and 5 more · For: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
Sites: Tucson, Arizona; Irvine, California; Los Angeles, California · 330 sites in all
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136624 · 1,310 participants (planned) · Start Dec 31, 2023 · Primary completion Nov 30, 2028
Drug: Opevesostat; Abiraterone acetate and 5 more · For: Prostate Cancer Metastatic
Sites: Orange, California; Palo Alto, California; Riverside, California · 288 sites in all
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06863272 · 360 participants (planned) · Start Jul 3, 2025 · Primary completion Oct 1, 2031
Drug: Docetaxel; Ifinatamab Deruxtecan and 4 more · For: Castration-Resistant Prostatic Cancer; Metastasis
Sites: Los Angeles, California; Orange, California; San Francisco, California · 82 sites in all
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07908524 · 290 participants (planned) · Start Dec 14, 2026 · Primary completion Jun 29, 2032
Drug: Sacituzumab tirumotecan; Rescue medication and 8 more · For: Metastatic Castration-resistant Prostate Cancer
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06979596 · 250 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 4, 2027
Drug: Opevesostat; Fludrocortisone/ Fludrocortisone acetate and 7 more · For: Malignant Neoplasm
Sites: Anchorage, Alaska; Miami Beach, Florida; Shreveport, Louisiana · 60 sites in all
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06353386 · 220 participants (planned) · Start May 20, 2024 · Primary completion Jan 15, 2029
Drug: Opevesostat; Olaparib and 5 more · For: Prostatic Neoplasms, Castration-Resistant
Sites: La Jolla, California; Los Angeles, California; Miami, Florida · 77 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06860243 · 16 participants · Start May 13, 2025 · Primary completion Feb 9, 2026
Drug: Opevesostat; Prednisone and 1 more · For: Hepatic Impairment; Healthy Participants
Sites: Miami, Florida; San Antonio, Texas
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07548606 · 14 participants · Start May 11, 2026 · Primary completion Jun 1, 2026
Drug: Opevesostat; Prednisone and 2 more · For: Healthy
Sites: Lincoln, Nebraska
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06633419 · 14 participants · Start Dec 18, 2024 · Primary completion Feb 12, 2025
Drug: Opevesostat; Prednisone and 2 more · For: Healthy
Sites: Tempe, Arizona
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136598 · 14 participants · Start Jan 30, 2024 · Primary completion Mar 9, 2026
Drug: Opevesostat; Dexamethasone and 2 more · For: Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer
Sites: Beijing, China; Guangzhou, China; Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Design, synthesis, and biological evaluation of 4H-pyran-4-one-based CYP11A1 inhibitors.
Yuan J, Wang D, Sun Y, et al. · Bioorg Med Chem Lett 2026
- Design, synthesis, and biological evaluation of cytochrome P450 CYP11A1 inhibitors.
Wang D, Cui S, Yuan J, et al. · Bioorg Med Chem Lett 2026
- Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.
Yu EY, Gratzke C, Burotto M, et al. · Future Oncol 2026
- Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology.
Kango G, Malek R, Mannuel H, et al. · Curr Opin Oncol 2024
- Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
· NEJM Evid 2024
- Statistics of Rare Events.
Proschan MA, Kherabi Y · NEJM Evid 2024
Also in development for Prostate Cancer Metastatic
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- luxdegalutamideJSB462, ARV-766Phase 24 trials
Novartis · Prostatic Cancer, Castration-Resistant, Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer Metastatic
- ADI-212Phase 21 trial
Adicet Therapeutics · Prostate Cancer Metastatic
- CC-38Phase 21 trial
CuraCell TX AB · Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.